The researchers also demonstrated that late-life MOTS-C treatment (initiated at 23.5 months, which is equivalent to roughly 70 human years) improved physical capacity and healthspan
(2018) 13:e0198024
Simply contact our TrimRx office in Tulsa to schedule your initial consultation
The Steering Committee has carefully reviewed published evidence on the management of dyslipidaemia, including its diagnosis, treatment, and prevention, as well as critical evaluation of diagnostic and therapeutic procedures, including benefit-risk assessment and cost-effectiveness indicators
This Website does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on this website
This study is particularly valuable because using an active comparator controls for many confounding factors